Biome Diagnostics
Biome Diagnostics (BiomeDx) is an Austrian MedTech company advancing precision medicine through microbiome profiling. Their flagship product, BiomeOne®, is the world's first stool-based prediction test for immunotherapy (ICI) response in cancer patients, launched in early 2022. BiomeDx combines intestinal microbiome analysis with advanced machine learning and proprietary databases to identify microbial signatures that predict treatment efficacy and potential side effects. The company is ISO 9001 and ISO 13485 certified, highlighting a commitment to quality and safety in medical devices. They aim to integrate their microbiome diagnostics into routine clinical practice to improve cancer care.
Biome Diagnostics
Biome Diagnostics (BiomeDx) is an Austrian MedTech company advancing precision medicine through microbiome profiling. Their flagship product, BiomeOne®, is the world's first stool-based prediction test for immunotherapy (ICI) response in cancer patients, launched in early 2022. BiomeDx combines intestinal microbiome analysis with advanced machine learning and proprietary databases to identify microbial signatures that predict treatment efficacy and potential side effects. The company is ISO 9001 and ISO 13485 certified, highlighting a commitment to quality and safety in medical devices. They aim to integrate their microbiome diagnostics into routine clinical practice to improve cancer care.